【藥品性質提示】 ★LASA藥品：NIV02 G-CSF (Nivestim) 針 綠 300mcg (形似) 點擊看LASA藥品外觀比較圖

Treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis (ESRD) and patients not on dialysis; anemia associated with chemotherapy for nonmyeloid malignancies.

Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect.

Onset of action: increased hemoglobin levels not generally observed until 2-6 weeks after initiating treatment; Bioavailability (SC): ~37% (range: 30% to 50%); Elimination half-life: 21 hr (IV), 49 hr (SC); Half-life is ~3 times as long as epoetin alfa.

Hypersensitivity to darbepoetin or any component of the formulation (including polysorbate 80 and/or albumin); uncontrolled hypertension

C

Excretion in breast milk unknown/use caution

Hypertension, hypotension, edema, fatigue, seizure, fever, headache, dizziness, diarrhea, vomiting, abdominal pain, nausea, dyspnea, infection, thrombosis, rash, pruritus.

Initial: 0.45 mcg/kg once weekly, titration to response; some patients may respond to doses given once every 2 weeks.

Store at 2-8℃, Do not freeze or shake